Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial

European Journal of Cancer

Volumn 45, Issue 7, 2009, Pages 1201-1208

  Mook, S ^a   Bonnefoi, H ^b   Pruneri, G ^c   Larsimont, D ^d   Jaskiewicz, J ^e   Sabadell, M D ^f   MacGrogan, G ^g   van't Veer, L J ^a,h   Cardoso, F ^d   Rutgers, E J ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF MILAN   (Italy)

^d JULES BORDET INSTITUTE   (Belgium)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g INSTITUT BERGONIÉ   (France)

^h Agendia NV   (Netherlands)

Author keywords

Breast cancer; Feasibility study; Gene expression signatures; Logistics

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL PRACTICE; CONTROLLED STUDY; CRYOPRESERVATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RNA ISOLATION; TISSUE PRESERVATION; TUMOR BIOPSY; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL TRIALS AS TOPIC; CRYOPRESERVATION; EUROPE; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LOGISTIC MODELS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PILOT PROJECTS; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 64049113346     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.01.004     Document Type: Article

References (35)

1. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
2. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
3. van de Vijver M.J., He Y.D., van 't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med 347 (2002) 1999-2009
4. Chang J.C., Wooten E.C., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
5. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 351 (2004) 2817-2826
6. Chang H.Y., Nuyten D.S.A., Sneddon J.B., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102 (2005) 3738-3743
7. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23 (2005) 7265-7277
8. Hannemann J., Oosterkamp H.M., Bosch C.A., et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 23 (2005) 3331-3342
9. Iwao-Koizumi K., Matoba R., Ueno N., et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23 (2005) 422-431
10. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
11. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
12. Hess K.R., Anderson K., Symmans W.F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24 (2006) 4236-4244
13. Potti A., Dressman H.K., Bild A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 12 (2006) 1294-1300
14. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262-272
15. Thuerigen O., Schneeweiss A., Toedt G., et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 24 (2006) 1839-1845
16. Bonnefoi H., Potti A., Delorenzi M., et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 8 (2007) 1071-1078
17. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98 (2006) 1183-1192
18. Bueno-de-Mesquita JM, Linn SC, Keijzer R, et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat [in press].
19. Mook S, Schmidt MK, Viale G, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat [in press].
20. Wittner B.S., Sgroi D.C., Ryan P.D., et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 14 (2008) 2988-2993
21. Masuda N., Ohnishi T., Kawamoto S., Monden M., and Okubo K. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucl Acids Res 27 (1999) 4436-4443
22. Cronin M., Pho M., Dutta D., et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164 (2004) 35-42
23. Vonsattel J.P., Aizawa H., Ge P., et al. An improved approach to prepare human brains for research. J Neuropathol Exp Neurol 54 (1995) 42-56
24. Bueno-de-Mesquita J.M., van Harten W.H., Retel V.P., et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 8 (2007) 1079-1087
25. Bogaerts J., Cardoso F., Buyse M., et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 3 (2006) 540-551
26. Mook S., van't Veer L.J., Rutgers E.J., Piccart-Gebhart M.J., and Cardoso F. Individualization of therapy using Mammaprint: from development to the MINDACT trial. Cancer Genom Proteom 4 (2007) 147-155
27. Cardoso F., Van't Veer L., Rutgers E., Loi S., Mook S., and Piccart-Gebhart M.J. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26 (2008) 729-735
28. Glas A.M., Floore A., Delahaye L.J., et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genom 7 (2006) 278-287
29. Camp R.L., Charette L.A., and Rimm D.L. Validation of tissue microarray technology in breast carcinoma. Lab Invest 80 (2000) 1943-1949
30. Bammler T., Beyer R.P., Bhattacharya S., et al. Standardizing global gene expression analysis between laboratories and across platforms. Nat Meth 2 (2005) 351-356
31. Dobbin K.K., Beer D.G., Meyerson M., et al. Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res 11 (2005) 565-572
32. Irizarry R.A., Warren D., Spencer F., et al. Multiple-laboratory comparison of microarray platforms. Nat Meth 2 (2005) 345-350
33. Florell S.R., Coffin C.M., Holden J.A., et al. Preservation of RNA for functional genomic studies: a multidisciplinary tumor bank protocol. Mod Pathol 14 (2001) 116-128
34. Mutter G.L., Zahrieh D., Liu C., et al. Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genom 5 (2004) 88-94
35. Leyland-Jones B.R., Ambrosone C.B., Bartlett J., et al. Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol 26 (2008) 5638-5644